AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Fasenra (benralizumab) — Worldwide product sales by Year
Fasenra (benralizumab) — Worldwide product sales ($M) ($M)
AstraZeneca Fasenra (benralizumab) — Worldwide product sales: $1,981M in FY2025, up 17.3% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Fasenra | 1,981 | 17 | 16 | 1,195 | 14 | 117 | 27 | 29 | 482 | 19 | 15 | 187 | 29 | 30”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Fasenra (benralizumab) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,981 | +17.3% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 1,689 | +8.8% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 1,553 | +11.2% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 1,396 | +11.0% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 1,258 | +32.6% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 949 | +34.8% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 704 | +137.0% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 297 | +29,600.0% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 1 | – | Form 20-F (filed 2019-03-05) ↗ |
Breakdown
What makes up fasenra (benralizumab) — Worldwide product sales
- Fasenra (benralizumab) — Worldwide YoY actual (%)17.0% · FY2025
- Fasenra (benralizumab) — Worldwide YoY CER (%)16.0% · FY2025
- Fasenra (benralizumab) — US product sales ($M)1,195 · FY2025
- Fasenra (benralizumab) — Emerging Markets product sales ($M)117 · FY2025
- Fasenra (benralizumab) — Europe product sales ($M)482 · FY2025
- Fasenra (benralizumab) — Established RoW product sales ($M)187 · FY2025
Cite this data
StockData. (2026). AstraZeneca Fasenra (benralizumab) — Worldwide product sales ($M), annual FY2017–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-fasenra-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.